On 10 August 2015, orphan designation (EU/3/15/1533) was granted by the European Commission to Bone Therapeutics SA, Belgium, for human allogeneic bone-marrow-derived osteoblastic cells for the treatment of osteogenesis imperfecta.

Key facts

Active substance
Human allogeneic bone-marrow-derived osteoblastic cells
Disease / condition
Treatment of osteogenesis imperfecta
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Bone Therapeutics SA
Rue Auguste Piccard 37
6041 Gosselies
Tel. +32 2 529 59 90
Fax +32 2 529 59 93

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating